Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …

Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

Pancreatic cancer is a highly malignant digestive system tumor with a poor prognosis. Most
pancreatic cancer patients are diagnosed at an advanced stage or even metastasis due to …

Pancreatic ductal adenocarcinoma (PDAC), generally known as pancreatic cancer (PC),
ranks the fourth leading cause of cancer-related deaths in the western world. While the …

Abstract Carbohydrate antigen 19-9 (CA19-9) is the best validated biomarker and an
indicator of aberrant glycosylation in pancreatic cancer. CA19-9 functions as a biomarker …

The metastasis is a multistep process in which a small proportion of cancer cells are
detached from the colony to enter into blood cells for obtaining a new place for metastasis …

Pancreatic cancer (PC) is a leading cause of cancer related mortality on a global scale. The
disease itself is associated with a dismal prognosis, partly due to its silent nature resulting in …

Tumor cell–derived extracellular vesicles (EVs) are being explored as circulating
biomarkers, but it is unclear whether bulk measurements will allow early cancer detection …

Pancreatic cancer is an aggressive malignancy with increasing incidence and poor
prognosis due to its late diagnosis and intrinsic chemoresistance. Most pancreatic cancer …

Introduction: In recent years, extensive research has been conducted on using exosomes as
biomarkers for cancer detection. Exosomes are 40–150 nm-sized extracellular vesicles …